DRugwatch BlogRSS 2.0

DRugwatch Blog > June 2011 > With Results From the ARISTOTLE Trial on the Horizon, What Are Eliquis’s Prospects for Success in th

With Results From the ARISTOTLE Trial on the Horizon, What Are Eliquis’s Prospects for Success in the Atrial Fibrillation Market?

Matt KileenWritten by: Matthew Killeen, Ph.D.

Summary
The stroke prevention for atrial fibrillation (SPAF) drug market is witnessing a sea change. Following the much welcomed launch of Pradaxa (Boehringer Ingelheim’s dabigatran etexilate) in the U.S. in October 2010, and the presentation of data from Xarelto’s (Bayer/J&J’s rivaroxaban) ROCKET-AF study, in November 2010, physicians are eagerly awaiting the results from Eliquis’s (BMS/Pfizer’s apixaban) Phase III ARISTOTLE trial. Although Eliquis is expected to be the third of the new oral anticoagulants to launch for this increasingly lucrative indication, will its profile and clinical performance enable it to gain a foothold in this market?

Analysis
Eliquis has undergone a unique clinical development program for SPAF. Its first Phase III study, the AVERROES trial, compared the drug to aspirin for stroke prevention in patients who were unable or unwilling to take warfarin. Based on Eliquis’s clearly superior efficacy over aspirin, seen in an interim analysis, AVERROES was prematurely terminated and its positive results were presented in August 2010 at the European Society of Cardiology (ESC) conference. While experts interviewed by Decision Resources welcomed new Phase III data for another replacement to warfarin, Eliquis’s superiority over aspirin was seen as no great surprise (in the ACTIVE-W SPAF trial, for example, warfarin clearly out performed a combination of aspirin and Plavix).

Eliquis’s bleeding profile in AVERROES garnered a great deal of attention from experts that we interviewed – the rates of major bleeding were not significantly different between Eliquis and aspirin – and we believe that this is one area where it has the greatest potential to differentiate itself from rival drugs (Pradaxa and Xarelto were both shown to have comparable rates of bleeding to warfarin in their Phase III trials). Indeed new results from Eliquis’s Phase II SPAF trial in Japanese patients (the ARISTOTLE-J Study), published last week, revealed that the drug was associated with a reduced rate of major or clinically-relevant non-major bleeding compared to warfarin (1.4% vs. 5.3%). Although these data are encouraging, the overall rates of bleeding with both drugs were vey low in this small 222 patient study. A true measure of Eliquis’s safety and efficacy, relative to warfarin, will be provided from the pivotal Phase III ARISTOTLE trial, results from which are expected later this year. Based on currently available data, and thought leader insight, what are some likely outcomes from ARISTOTLE?

We expect Eliquis to have similar efficacy to warfarin in ARISTOTLE alongside a stronger safety profile. At the very least, we expect the drug to have a significantly reduced risk of intracranial haemorrhage, relative to warfarin, as has already been seen with Pradaxa and Xarelto. We also expect that Eliquis has the potential to show a trend towards lower rates of major bleeding in ARISTOTLE; a statistically significantly reduction in this endpoint, however, will be much tougher to achieve.

We predict a first launch for Eliquis in 2012 for SPAF. Eliquis is therefore likely to enter the market behind Pradaxa and Xarelto and, although these prior launches may further prime physicians to the concept of new oral agents to replace warfarin, overcoming these more established brands will be no simple feat. Alongside its first-to-market advantage, for example, Pradaxa was shown to have superior efficacy over warfarin in its Phase III trial (Xarelto, on the other hand, had a similar level of efficacy to warfarin in its study). Finally, as with Pradaxa, Eliquis is dosed twice daily and any advantages that it could offer in terms of lower rates of bleeding could be offset by this dosing requirement. Given the expected long treatment durations with the new anticoagulants for SPAF, a once daily drug, such as Xarelto, may well emerge as the preferred choice.



Posted on: 6/21/2011 1:04:12 PM | with 0 comments


Tags: Cardiovascular, Matt Killeen

Trackback URL: http://decisionresources.com/trackback/abf59c5a-9789-4f35-bac0-522e477a5852/With-Results-From-the-ARISTOTLE-Trial-on-the-Horizon,-What-Are-Eliquis’s-Prospects-for-Success-in-th.aspx?culture=en-us

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
New Year, new resolutions, new drugs
Post date:
12/17/2014 10:53:24 AM
Post Summary:
 Contributors: Tim Blackstock

It’s a wonderful time of the year: spending quality time with friends and family, and eating good food. And then it’s January, and you hop on the scales – and then you hop off quickly in disbelief – how can it take such a short time to add so many pounds when it takes so long to lose just a few?!

Post title:
Pfizer Increases Enrollment by 40% in the SPIRE Cardiovascular Outcomes Trials for PCSK9 Inhibitor Bococizumab
Post date:
11/11/2014 9:36:25 AM
Post Summary:
Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).

Post title:
Obesity Week 2014 - Belviq gets the combination treatment
Post date:
11/7/2014 10:07:43 AM
Post Summary:
Gideon HeapContributor: Gideon Heap

Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.


Post title:
What’s going to be Hot at the 2014 AHA Scientific Sessions?
Post date:
10/22/2014 5:22:24 PM
Post Summary:
  Contributor: Conor Walsh

 This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

  • Risk and benefit of dual antiplatelet therapy (DAPT),
  • Anti-lipid therapy and prevention of coronary artery disease,
  • Treatment of structural heart disease
  • Drugs, devices and systems of care for ischemic heart disease.

Post title:
Advancing the Treatment of TKI-refractory NSCLC
Post date:
10/9/2014 1:33:46 PM
Post Summary:
Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

Decision Resources Group brands include: